Greenwich LifeSciences (GLSI) Net Cash Flow (2019 - 2025)
Greenwich LifeSciences (GLSI) posted Net Cash Flow of $2.4 million for Q4 2025, up 247.72% on a QoQ basis from $681877.0 in Q3 2025, and up 237.02% year-over-year from $703522.1 in Q4 2024.
Greenwich LifeSciences (GLSI) Net Cash Flow (2019 - 2025) Analysis & Trends
Greenwich LifeSciences' Net Cash Flow history runs 7 years deep, the most recent figure standing at $2.4 million for Q4 2025.
- Quarterly Net Cash Flow rose 237.02% year-over-year to $2.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.1 million (up 172.0% YoY) and the FY2025 annual result came in at $2.1 million, up 172.0% from the prior year.
- Net Cash Flow was $2.4 million for Q4 2025 at Greenwich LifeSciences, up from $681877.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $2.4 million in Q4 2025 and bottomed at -$7.5 million in Q1 2022.
- A 5-year average of -$1.1 million and a median of -$1.4 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 527.68% — and 2024, when it jumped 277.76%.
- Greenwich LifeSciences' Net Cash Flow stood at -$1.7 million in 2021, then retreated by 27.52% to -$2.2 million in 2022, then climbed by 0.73% to -$2.2 million in 2023, then increased by 19.67% to -$1.7 million in 2024, then soared by 237.02% to $2.4 million in 2025.
- Business Quant data shows GLSI's Net Cash Flow at $2.4 million in Q4 2025, $681877.0 in Q3 2025, and $375142.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Greenwich LifeSciences | 178.53 Mn | 178.53 Mn | - | 2.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.37 Mn |
| Dec 31, 2025 | 2.37 Mn |
| Sep 30, 2025 | 681,877.00 |
| Sep 30, 2025 | 681,877.00 |
| Jun 30, 2025 | 375,142.00 |
| Jun 30, 2025 | 375,142.00 |
| Mar 31, 2025 | -1.34 Mn |
| Mar 31, 2025 | -1.34 Mn |
| Dec 31, 2024 | -1.73 Mn |
| Dec 31, 2024 | -1.73 Mn |
| Sep 30, 2024 | -1.40 Mn |
| Sep 30, 2024 | -1.40 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Jun 30, 2024 | 1.72 Mn |
| Mar 31, 2024 | -1.48 Mn |
| Mar 31, 2024 | -1.48 Mn |
| Dec 31, 2023 | -2.15 Mn |
| Dec 31, 2023 | -2.15 Mn |
| Sep 30, 2023 | -1.80 Mn |
| Sep 30, 2023 | -1.80 Mn |